Anthim obiltoxaximab: Phase III data

Elusys said data from a double-blind, placebo-controlled, U.S. Phase III trial in 280 healthy adult volunteers support the safety and

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE